Oppenheimer Maintains Outperform on Biogen, Maintains $270 Price Target

Biogen Inc. -0.70%

Biogen Inc.

BIIB

224.00

-0.70%

Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ: BIIB) with a Outperform and maintains $270 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via